Puma Biotechnology Inc
Puma Biotechnology is a U.S.-based biopharmaceutical company focused on developing and commercializing oncology therapies. Its core commercial product is NERLYNX, an oral neratinib treatment for certain HER2-positive breast cancers, and it also holds global rights to develop and commercialize alisertib, a small-molecule Aurora Kinase A inhibitor.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSales of NERLYNX for approved HER2-positive breast cancer indications.
Royalties earned from sub-licensee sales of NERLYNX in international territories.
Development activities for alisertib and related clinical programs.
Tuotteet
Raportoitu · osuus liikevaihdosta- Products89,4 %
- Royalty10,6 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Puma sells NERLYNX primarily through a limited number of U.S. specialty pharmacies and specialty distributors, which then dispense the product to patients and certain medical centers or hospitals. It also earns royalty revenue from sub-licensees that commercialize NERLYNX in international territories. The business is therefore tied to oncology prescribing, payer access, and the purchasing behavior of a concentrated channel network.
Buy NERLYNX for dispensing to patients under prescription and are a core channel for product revenue.
Purchase and distribute NERLYNX into oncology care settings and support product availability.
Commercialize NERLYNX in their territories and generate royalty revenue for Puma.
Influence adoption by selecting NERLYNX for eligible HER2-positive breast cancer patients.
Strategia
Puma’s strategy centers on extending NERLYNX commercialization while funding development of alisertib as a second oncology asset. The company also relies on third-party manufacturing, regulatory, and distribution partners, so execution depends on maintaining supply, access, and clinical progress across a narrow product base.
The product is the company’s main revenue engine and requires payer access and physician adoption.
A second oncology asset could diversify the business beyond a single commercial product.
Sub-license arrangements provide royalty revenue without building a large overseas commercial footprint.
Maantiede
Puma is headquartered in the United States and its direct commercial operations are centered there, where it maintains an oncology sales force and related commercial infrastructure. Outside the U.S., the company participates through sub-license arrangements that generate royalty revenue from international territories, including sales activity in China. Geography matters because reimbursement, pricing, and regulatory approval differ by market and directly affect uptake.
Riskit
Puma is exposed to concentrated product and customer risk because most revenue depends on NERLYNX and a limited number of specialty channel customers. It also faces clinical, regulatory, manufacturing, and reimbursement risk typical of oncology biopharma, where competitor products, pricing pressure, and trial outcomes can quickly alter commercial prospects.
- Customer concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
A limited number of specialty pharmacies and distributors account for a large share of product revenue, so losing one can materially affect sales.
Kohdistuu - Competitive pressure in oncologyVaikutus: KorkeaTodennäköisyys: Kohtalainen
Other approved or emerging therapies may offer better safety, efficacy, convenience, pricing, or reimbursement access.
Kohdistuu: NERLYNX and future pipeline products compete in HER2-positive and broader oncology markets.
- Development and regulatory riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Alisertib depends on successful clinical development and regulatory approval before it can become a meaningful product.
Kohdistuu: Small cell lung cancer and hormone receptor-positive breast cancer programs.
- International royalty exposureVaikutus: KeskitasoTodennäköisyys: Korkea
Royalty revenue depends on sub-licensee sales in foreign markets, which can fluctuate with local demand and competition.
Kohdistuu - Manufacturing and supply dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company relies on third-party contractors for drug substance, drug product, storage, and distribution.
Kohdistuu: NERLYNX commercial supply and alisertib clinical supply.
Kirjanpito
Harkinnanvaraiset erätNERLYNX product revenue is recorded net of rebates, chargebacks, discounts, and other variable consideration, which can materially change reported sales.
Vaikutus: Affects product revenue timing and net sales margin
Royalty income from sub-licensees is recognized when underlying sales occur, so international demand directly drives reported revenue.
Vaikutus: Affects quarterly and annual revenue volatility
Changes in the allowance can create large non-cash tax benefits or expenses.
Vaikutus: Can materially affect net income
The Takeda license includes potential milestone payments and other contingent obligations that depend on future events.
Vaikutus: Affects liabilities and future cash outflows
Uncertain tax positions and legal contingencies require estimates of probable losses and amounts.
Vaikutus: Affects accrued liabilities and earnings
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Tyra Biosciences, Inc.
TYRA · Pharmaceutical Preparations
Kura Oncology, Inc.
KURA · Pharmaceutical Preparations
Cogent Biosciences, Inc.
COGT · Pharmaceutical Preparations
TuHURA Biosciences, Inc.
HURA · Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV is a Nevada-based clinical-stage immuno-oncology company focused on developing therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.
Nuvalent, Inc.
Pharmaceutical Preparations
Päivitetty: 24.9.2026